Affectis Granted Patent for AFC-5128, other P2X7 Antagonists

(PresseBox) ( Martinsried, )
Affectis Pharmaceuticals AG, a pharmaceutical company developing novel drugs for the treatment of neuroinflammatory diseases, announced today that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis.

The European patent EP2105164 is related to the composition of AFC-5128, a highly potent orally active P2X7 antagonist. A key advantage of the compound is its ability to cross the blood-brain barrier and target P2X7-expressing CNS-cells such as glia and oligodendrocyte cells which are linked to neurodegenerative processes. Affectis has shown that oral administration of AFC-5128 significantly reduces clinical scores and frequency of relapse in a mouse model of multiple sclerosis. Strong analgesic effects have also been observed in animal models of inflammatory and neuropathic pain. With these efficacy data available, Affectis is on track for filing an IND in 2012 for neuropathic pain and multiple sclerosis.

The granted patent also covers the composition of further P2X7 antagonist compounds. Affectis has filed corresponding patent applications that are being processed in major markets such as the USA, Japan, China, among others.

Dr. Manfred Ruediger, CEO of Affectis, commented, "The issuance of this patent, the confirmation of the efficacy of AFC-5128 in various animal models and the license agreement entered with Merck Serono on a separate program are all important achievements that occurred in the past year."
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an service@pressebox.de.